Therapeutic Potential of Non-Coding RNAs and TLR Signalling Pathways in Rheumatoid Arthritis

Author(s): Jingjing Liu, Xiaoxu Wang, Shufeng Wang*, Fengxia Liu*

Journal Name: Current Pharmaceutical Biotechnology

Volume 22 , Issue 11 , 2021


Become EABM
Become Reviewer
Call for Editor

Abstract:

Background: Rheumatoid Arthritis (RA) is a common connective tissue disease, characteristic of chronic and invasive synovitis in single or multiple joints and vasculitis. RA is a heterogeneous disease with unclear pathogenesis. Therefore, exploring the etiology and pathogenesis of the disease is essential for identifying new promising treatment strategies for RA. Accumulated data have implicated the significant role of non-coding RNA in RA, some of which are demonstrated to regulate inflammation and autoimmunity in RA through the Toll-Like Receptor (TLR) signaling pathway. To clarify the mechanism of non-coding RNA regulating the generation of proinflammatory mediators is helpful for understanding the pathogenesis of RA. Moreover, these well established non-coding RNAs can serve as novel biotargets for RA diagnosis and treatment.

Conclusion: Here, we summarize currently available data on non-coding RNAs, TLRs, and the underlying molecular mechanisms in RA. This review will provide insight into the potential use of noncoding RNA as disease diagnosis and treatment markers for RA.

Keywords: Non-coding RNA, toll-like receptor, NF-κB, rheumatoid arthritis, signaling pathway, pathogenesis.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 22
ISSUE: 11
Year: 2021
Page: [1490 - 1500]
Pages: 11
DOI: 10.2174/1389201021666201001142829
Price: $95

Article Metrics

PDF: 68